Inclusion Criteria:

- Histologically or cytologically confirmed solid tumors that fulfill ≥ 1 of the
following criteria:

- BRCA1/2 mutation and a BRCA-related malignancy

- Patients without a known BRCA mutation must have a probability of harboring
a BRCA gene mutation as assessed by BRCAPRO computer program

- Patients with a probability of having genetic mutation ≥ 20% or a BRCA
mutation based on a non-Myriad test, must have a formal BRCA testing by
Myriad Genetic Laboratories

- Patients with known deleterious BRCA 1 or 2 mutation or a mutation of
uncertain significance

- Patients who refuse BRCA testing not allowed unless they have another
acceptable histology

- First- or second-line metastatic colorectal cancer

- Any-line metastatic mucinous ovarian cancer

- Any line of other metastatic gastrointestinal malignancies in which oxaliplatin
has shown some activity (i.e., gastric or pancreatic adenocarcinoma)

- Patients with uncontrolled CNS metastasis are not eligible; patients with CNS
metastases who have had them treated and are stable for > 3 months will be eligible;
patients must be off steroid treatment prior to study enrollment

- Measurable disease

- Patients with ovarian cancer who have a pre-treatment CA 125 level of at least
twice the upper limit of normal allowed

- ECOG performance status (PS) 0-2 (Karnofsky 60-100%)

- Life expectancy > 3 months

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)

- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min

- Fertile patients must use adequate contraception (i.e., hormonal, barrier method of
birth control, or abstinence)

- Not pregnant or nursing

- Negative pregnancy test

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to veliparib or other agents used in study

- No uncontrolled intercurrent illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness and/or social situations that would limit compliance with
study requirements

- No history of positive serology for hepatitis A, B, or C, liver disease, or other
forms of hepatitis or cirrhosis

- Patients who have active seizures or history of seizures are ineligible

- No condition that impairs the ability to swallow and retain veliparib capsules,
including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication
or a requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No malabsorption syndrome, disease significantly affecting gastrointestinal function,
resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel
disease, or a partial or complete small bowel obstruction

- No peripheral neuropathy ≥ grade 2

- No prolonged QTC > 450 msec (male) or QTC > 470 (female)

- No concurrent combination antiretroviral therapy for HIV-positive patients

- Recovered from adverse events of prior therapy or prior surgical procedures

- Patients with chronic grade 1 or 2 adverse events that are not expected to
improve are allowed at investigator's discretion

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- At least 4 weeks since prior radiotherapy with no > 35% of marrow irradiation

- Prior fluoropyrimidine allowed

- Prior veliparib allowed provided it was part of a single- or limited-dosing study,
such as a phase 0 study

- Prior capecitabine allowed provided patient tolerated 3500 mg/m² for 7 days out of 14
days

- No other prior investigational agents

- No prior oxaliplatin